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SUMMARY 
Animal experiments indicate that angiotensin I1 can, under some circumstances 
stimulate the sympathetic nervous system at a number of different sites. In order 
to determine whether such a relationship of the renin-angiotensin and sympath- 
etic nervous system exists in man, we increased (by intravenous infusion), or 
decreased (by administering the oral converting enzyme inhibitor captopril) 
circulating angiotensin I1 levels and monitored plasma adrenaline and nor- 
adrenaline responses. Angiotensin I1 infusions did not increase plasma cate- 
chol-amines, and lowering of angiotensin I1 by captopril treatment in patients 
with severe hypertension or congestive heart failure failed to alter plasma 
adrenaline or nor-adrenaline levels. Whether physiological levels of angiotensin 
I1 are capable of interacting directly with the sympathetic nervous system in 
man remains to be demonstrated. 
There is a vast literature attesting to interactions of the renin-angiotensin and sympathe- 
tic nervous systems (McCubbin, 1974). Whereas animal experiments leave no doubt that 
angiotensin I1 in large doses can stimulate the sympathetic system at multiple sites, it is 
less clear whether such an interaction occurs at physiological levels of angiotensin I1 in 
man. 
In the present human studies we have increased or decreased plasma angiotensin I1 
levels, and monitored catecholamine responses in plasma in an attempt to define whether 
angiotensin I1 is capable of altering sympathetic activity. 
METHODS 
The human studies were approved by the Human Use Committee of the University of 
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Michigan Medical Center or the Ethical Committee of the North Canterbury Hospital 
Board, Christchurch, New Zealand. 
Angiotensin ZI infusion in normal subjects 
Five healthy male volunteers, aged 22-28 years, were studied in the Clinical Research 
Centre at the University of Michigan Medical Center. Each subject received a constant 
intake of dietary sodium (40 mmol/day) and potassium (100 mmol/day) for 4 days prior 
to angiotensin I1 infusions on day five. Smoking, caffeine-containing beverages, and 
vigorous physical exercise were avoided. On day 5 the volunteers remained supine in bed, 
and a venous cannula was inserted into either arm at 0800 h, one for infusion, the other for 
sampling. After 60 min of 5% dextrose administration at 0.2 ml/min, angiotensin I1 
(Hypertensin, Ciba) was infused incrementally at 0 3 1  *O, 2.0 and 4.0 ng.kg-].min-’, each 
rate for 1 h. Two venous samples were drawn during dextrose administration and single 
samples were obtained at the completion of each infusion rate of angiotensin I1 for 
measurement of nor-adrenaline, adrenaline and angiotensin 11. Blood was taken into 
pre-chilled containers, immediately centrifuged at 4”C, and the plasma stored at - 20°C 
until analysed. Blood pressure was measured at 10 min intervals using a standard mercury 
sphygmomanometer taking phase V as the diastolic endpoint: the mean of six recordings 
was taken as the blood pressure for each hour of infusion. 
Blockade of angiotensin II formation in severe hypertension 
Ten patients, nine male, one female, aged 28-53 years, five white, five black, with 
elevated blood pressure not controlled on conventional therapy were studied in the 
Clinical Research Center of the University of Michigan. Smoking and caffeine-containing 
drinks were avoided. In all patients, prior treatment consisting of propanolol(80 mg four 
times daily), hydrochlorothiazide (25 mg four times daily), and hydrallazine (50 mg four 
times daily) was discontinued on admission, and dose titration with the oral converting- 
enzyme inhibitor captopril (Squibb) started the following morning. With the patient 
supine in bed, captopril was administered at 2-hourly intervals in increasing dosage (25, 
50, 100 and 150 mg) until a ‘hypotensive’ response (fall in diastolic pressure phase V of at 
least 10 mmHg using a conventional mercury sphygmomanometer) was achieved. A 
venous cannula was inserted 30 min prior to a baseline (pre-captopril) sampling, and a 
second venous specimen was obtained once the ‘hypotensive’ response was reached. Both 
samples were handled as described above and analysed for plasma angiotensin 11, plasma 
renin activity (PRA), and plasma adrenaline and nor-adrenaline. 
Blockade of angiotensin II formation in congestive heart failure 
The oral converting enzyme inhibitor captopril, was administered to four male patients 
aged 62-72 years in the Intensive Care Unit, Princess Margaret Hospital, Christchurch, 
New Zealand. Details of haemodynamic and hormone responses have been reported 
(Maslowski et al.,  198 1). Each patient was in severe congestive cardiac failure (grade I11 or 
IV New York Heart Association classification) and had proven resistant to conventional 
therapy. A diet of constant sodium (3343 mmol/day) and potassium (73-100 mmol/day) 
was taken, and bedrest was enforced throughout the 7-10 day study. Digoxin (0.0625-0.5 
mg/day) and frusemide (1 20-500 mg/day) therapy was constant in each patient for the 
duration of the study. After a 2-day ‘run-in’ period of digoxin and frusemide therapy, 
captopril was administered at 0730 h, 1430 h and 2330 h starting at 6.25 mg and increasing 
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until a maximum of 150 mg per dose or an intra-arterial systolic pressure of 75 mmHg was 
reached. Blood samples for measurement of PRA, angiotensin 11, adrenaline and nor- 
adrenaline were drawn from an arterial catheter a t  0830 h and 1530 h each day, precisely 1 
h after captopril administration, and handled as described above. 
Plasma angiotensin I1 (Nicholls & Espiner, 1976) and PRA (Dunn & Espiner, 1976) 
were measured by radioimmunoassay. The radioenzymatic technique used to measure 
catecholamines (Peuler & Johnson, 1977) was capable of detecting 2.5 pg/tube of adrena- 
line or nor-adrenaline added to plasma. There was a straight line relationship between 
catecholamines added to plasma and final counts per minute from the assay over a range 
of 1&1000 pg adrenaline or nor-adrenaline per tube. From fifteen consecutive assays the 
interassay coefficient of variation was 17% (adrenaline) and 1 1% (nor-adrenaline): the 
intra-assay coefficient of variation was 8% (adrenaline) and 7% (nor-adrenaline). All 
samples from any one subject were analysed in a single assay. 
RESULTS 
Angiotensin II infusion in normal subjects 
Blood pressure did not change significantly until the highest infusion rate (4 
ng.kg-'.min-') was reached (Fig. 1 )  when the average increase in systolicpressure was 6 
mmHg and in diastolic pressure was 9 mmHg above baseline. The pulse rate of 58.2 & 3 
beats/min (mean k SEM) prior to angiotensin I1 administration was unaltered by infusion 
of the octapeptide (58.3 f 3.4 beats/min during the highest infusion rate). Despite incre- 
ments in plasma angiotensin I1 to approximately 100 pg/ml there was no clear response of 
adrenaline or nor-adrenaline (Fig. 1). 
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Fig. 1. Plasma hormone levels and arterial pressure (mean* SEM) in five volunteers prior to and 
during an incremental intravenous infusion of angiotensin 11. See Table 1 for conversion to SI 
units. 
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Fig. 2. Plasma hormone, arterial pressure and pulse rate responses to administration of the oral 
converting enzyme inhibitor captopril in four patients with congestive cardiac failure. Data are 
shown as meanfSEM. See Table 1 for conversion to SI units. Plasma renin activity -; 
plasma angiotensin 11 -. 
Blockade of angiotensin I I  formation in seuere hypertension 
Captopril treatment reduced angiotensin I1 levels in eight of ten patients, and PRA 
increased significantly (Table 1). On the contrary, plasma catecholamines were not altered 
for the group as a whole (Table I), nor in the eight patients in whom a clear-cut decline in 
angiotensin I1 occurred (three showing either no change or a rise in adrenaline and 
nor-adrenaline levels). 
Angiotensin 11 and catecholamines 
Table 1. Plasma hormone concentrations (mean f 
SEM) from ten hypertensive patients before and after 
captopril therapy 
Pre-captopril Capropril 
PRA (ng.ml-'.h-') 1.61 k0.61 4.09*f 1.62 
Angiotensin I1 (pg/ml) 21.2k3.2 12.5k2.8 
Nor-adrenaline 177k33 189+37 
Adrenaline (pg/ml) 57+6 61 k9 
(pg/mI) 
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*P < 0.05 significance of change from pre-captopril 
value (paired r test). 
Conversion to SI units: PRA 1 ng.ml-'.h-'=0.77 
nmol.-'.h-'; angiotensin I1 1 pg/ml=0.95 pmol/l; 
nor-adrenaline 1 ng/ml= 5.91 nmol/l; adrenaline 1 
ng/ml= 5.46 nmol/l. 
Blockade of angiotensin IIformation in congestive heart failure 
Adrenaline and nor-adrenaline levels prior to administration of the oral converting- 
enzyme inhibitor were generally higher than values seen in healthy subjects. Captopril 
therapy induced clearcut decreases in plasma angiotensin I1 and increments in PRA, yet 
there was no fall in plasma catecholamines (Fig. 2 ) .  Pulse rates declined (Fig. 2) but the 
change failed to reach conventional levels of statistical significance. Arterial pressure was 
decreased by captopril therapy (Fig. 2).  
DISCUSSION 
There is no doubt that angiotensin I1 can alter the activity of the sympathetic nervous 
system under certain experimental circumstances (Campbell & Jackson, 1979; Peach, 
1971; Yu & Dickinson, 1971). Most of the data, however, are derived from animal studies 
where the doses of angiotensin I1 have been large. Whether one can extrapolate from these 
highly experimental animal data to physiological circumstances in man, is not known. 
Few workers have looked in detail at possible actions of angiotensin I1 on the 
sympathetic system in man, and what data are available appear contradictory. For 
example, McGrath et al. (1977) and Takishita et al. (1978) reported that the sympathetic 
nervous system was activated by the weak angiotensin agonist saralasin, whereas neither 
saralasin (Carey et al., 1978; Vlachakis et al., 1978) nor angiotensin I1 infusion (Mendel- 
sohn et al., 1980) altered plasma nor-adrenaline levels according to other authors. 
Likewise, blockade of angiotensin I1 formation with a converting enzyme inhibitor has 
been reported variously to increase (Heavey & Reid, 1978; Hulthen & Hokfelt, 1978) 
decrease (Curtiss et af., 1978; Turini et al., 1979), or have no effect (Bravo & Tarazi, 1979) 
on plasma nor-adrenaline levels in man under various circumstances. 
In order to define any action of angiotensin I1 on the sympathetic nervous system, we 
increased angiotensin I1 by infusion, or decreased endogenous angiotensin I1 levels with a 
converting enzyme inhibitor, and measured circulating catecholamine responses. Our 
subjects were studied under carefully controlled circumstances with attention to details of 
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body posture, the avoidance of venepuncture just prior to sampling, and prohibition of 
sympathetic stimulation from caffeine or smoking. The assays used were capable of 
detecting minor changes in catecholamine and angiotensin I1 concentrations. 
Under these conditions, we failed to observe any increase in plasma catecholamines in 
healthy volunteers during increments in plasma angiotensin I1 which were within physio- 
logical limits. Our results thus agree with the brief report by Mendelsohn et al. (1980) 
which indicated a lack of change in plasma nor-adrenaline levels across angiotensin I1 
infusion in normal man. Whether greater increments in angiotensin I1 beyond those seen 
under normal circumstances can alter sympathetic activity in man, remains to be seen. 
Conceivably, any action of angiotensin I1 on the sympathetic nervous system may be 
maximal at relatively low levels of circulating angiotensin 11. If this were so, increments in 
angiotensin I1 might not further activate the sympathetic system, but a reduction of 
angiotensin I1 levels from normal or high values should result in a lowering of circulating 
catecholamines. The current studies indicate that blockade of angiotensin I1 formation 
did not regularly alter circulating nor-adrenaline or adrenaline. Baseline levels of angio- 
tensin I1 were not high in our severe hypertensives, presumably because of prior beta- 
blocker therapy, and the reduction in plasma angiotensin I1 induced by captopril was 
therefore not great. In contrast, both angiotensin I1 and catecholamines were elevated in 
the patients with cardiac failure yet no change in circulating catecholamines was noted 
when angiotensin I1 levels exhibited a clearcut fall. 
In summary, we have shown that neither increments nor decrements in circulating 
angiotensin I1 alter plasma catecholamine levels, the humoral markers of sympathetic 
activity, in man. It is tempting to conclude therefore that angiotensin I1 has little or no 
action on the sympathetic nervous system, at least under the conditions of the present 
studies. It is possible nevertheless, that any action of angiotensin I1 was in part obscured 
by alterations of arterial baroreceptor input to the sympathetic system by a concomitant 
rise (during angiotensin I1 infusion) or fall (with captopril therapy) in blood pressure. 
However no change in catecholamines occurred in our normal subjects during 0.5-2 
ng.kg- '.min- ' angiotensin I1 infusion rates when little or no rise in arterial pressure had 
occurred. Likewise, captopril monotherapy reduced blood pressure in our hypertensives 
by little more than 10 mmHg, thus major baroreceptor stimulation would not be 
expected. It seems unlikely therefore that changes in blood pressure obscured an action of 
angiotensin I1 on the sympathetic nervous system. 
A complicating issue in the interpretation ofcaptopril studies is the fact that bradykinin 
levels would be expected to rise along with falls in angiotensin 11. Since bradykinin, like 
angiotensin I1 has been reported to stimulate adrenal medullary secretion (Feldberg & 
Lewis, 1964) it is conceivable that a reduction in sympathetic stimulation from falling 
angiotensin I1 was counterbalanced by augmented stimulation by rising bradykinin 
levels. Whether there are in fact distinct increases in plasma bradykinin across captopril 
treatment is open to dispute, and refinements of current methodologies for the measure- 
ment of this labile peptide are required for clarification. 
A final note of caution must be made regarding interpretation of the present results. 
There is some uncertainty whether plasma catecholamines reflect accurately the state of 
activity of the sympathetic nervous system under all circumstances. For example, Mancia 
et al. (1979) using a neck chamber technique showed that in normal subjects a reduction of 
baroreceptor activity had pressor effects without a concomitant change in plasma nor- 
adrenaline. Since the overspill of transmitter from sympathetic nerve endings into the 
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circulation is small, and because the clearance rate of nor-adrenaline released into plasma 
will almost certainly be altered under certain conditions, plasma levels of nor-adrenaline 
must be interpreted with caution. 
The current studies in man fail to demonstrate any action of angiotensin I1 to alter 
plasma adrenaline or nor-adrenaline levels, the humoral markers of sympathetic activity. 
Whether angiotensin I1 at physiological concentrations is capable of interacting directly 
with the sympathetic nervous system in man remains to be demonstrated. 
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